NFE2L2 and pulmonary fibrosis: YX-2102 ameliorated lung fibrosis by suppressing EMT in a CB2R dependent manner via regulation of the Nrf2/Smad7 pathway, indicating that CB2R is a potential therapeutic target for PF treatment.